In this episode (17:40), Medicom’s correspondent covers 6 presentations from the MSMilan 2023 (9th Joint ECTRIMS-ACTRIMS Meeting), 11–13 October, held in Milan, Italy.
The topics discussed are:
- Fenebrutinib shows rapid reduction of new Gd+ T1 lesions
Fenebrutinib penetrates the cerebrospinal fluid (CSF) at sufficient enough levels to reduce activation of B-cells and microglia in vitro. These early findings from the ongoing phase 2 study FENopta suggest that this new drug may impact mechanisms underlying chronic progressive disease-biology in MS. The study met its primary endpoint, with a 69% reduction in the number of new T1-lesions in weeks 4-12.. - Early initiation of highly active treatment associated with a lower risk of SPMS
A French, retrospective, multicentric register study evaluated the long-term impact of the early use of high-efficacy therapy (HET) on the occurrence of secondary progressive MS (SPMS). After 10 years, only 8.0% of patients treated early with HET converted to SPMS. This percentage is lower than would be expected when looking at the known natural history of MS, making the authors advocate for early introduction of HET in younger patients. - Smouldering inflammation detectable even in the earliest stages of MS
It may be that chronic lesion-associated smouldering inflammation is more pronounced in the later phase of the disease, but it can be detected from the earliest stages of MS, according to Finnish research. The prevalence of paramagnetic lesions (PRLs) was highest in patients with the shortest disease duration. - Positive phase 2 results for first-in-class anti-CD40L antibody
Efficacy and safety data at week 24 from the ongoing open-label part of the frexalimab phase 2 trial in relapsing MS were promising. This first-in-class anti-CD40L antibody was well tolerated and continued to demonstrate a marked reduction of new MRI lesions. Phase 3 trials for frexalimab are already in preparation. - Prioritising highly-effective therapies in children with MS
Highly-effective therapies (HET) as a first-line option in paediatric-onset MS (POMS) results in sustained reduction of clinical and radiological disease activity over 5 years, compared with first choosing moderately-effective therapies (MET). The results of their study prompt the French authors to advocate HET as first choice in children with MS. - Switching from rituximab to C5 complement inhibitors is safe in AQP4+ NMOSD
Many patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD) used rituximab prior to transitioning to C5 complement inhibitors (C5ITs). In these patients, safety outcomes in the PREVENT and CHAMPION-NMOSD studies were not different from patients who had not received prior rituximab. This is important to know for patients and caregivers when considering a switch.
Enjoy listening!
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Traditional Chinese medicine successful in HFrEF Next Article
Reprogramming stem cells to heal intestinal mucosa in IBD: fact or fiction? »
« Traditional Chinese medicine successful in HFrEF Next Article
Reprogramming stem cells to heal intestinal mucosa in IBD: fact or fiction? »
Table of Contents: MSMilan 2023
Featured articles
Letter from the Editor
Real-world data supports ocrelizumab prior to conception
Progressive MS
Early initiation of highly active treatment associated with a lower risk of SPMS
Ocrelizumab more effective than interferon/glatiramer acetate in older MS patients
Paediatric MS
Prioritising high efficacy therapies in children with MS
Omega-3 polyunsaturated fatty acids associated with lower risk of MS activity
NMOSD & MOGAD
An update on evolving treatment algorithms for NMOSD and MOGAD
Women’s Health
Rate of grey matter brain atrophy accelerates after menopause
Real-world data supports ocrelizumab prior to conception
Miscellaneous
New insights into the contribution of EBV to MS pathogenesis
COVID-19 infection associated with higher MS relapse rate
Telerehabilitation effective in improving MS symptoms in patients with moderate disability
Curing MS
Understanding what an MS cure means and what it takes
Prodromal MS
Progressive brain tissue loss precedes the onset of clinical MS by years
Sickness absence rate increases years before clinical onset of MS
Treatment Trials and MS Strategies
Early intensive treatment enhances long-term clinical outcomes
Oral glycolipid shows promise in the treatment of MS, especially SPMS
Fenebrutinib shows rapid reduction of new Gd+ T1 lesions
Challenges of de-escalation versus discontinuation of highly effective DMTs in older MS patients
Biomarkers & Imaging
χ-separation can assess the effects of tissue destruction in early MS lesions
High sGFAP levels are associated with disease progression, independent of NfL or relapse activity
Broad rim lesions correlate with a rapidly progressive MS phenotype
Smouldering inflammation detectable even in the earliest stages of MS
Related Articles
December 16, 2020
First long-term efficacy data of a BTK inhibitor
November 25, 2020
Low-dose rituximab as effective as high-dose, but safer
November 25, 2020
Safety and efficacy of dimethyl fumarate: 13 years of follow-up
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com